FDA Grants Fast Track Designation to YUTREPIA® for the Treatment of Raynaud's Phenomenon Associated with Systemic Sclerosis
Liquidia (Nasdaq: LQDA): FDA grants Fast Track designation to YUTREPIA for systemic sclerosis-associated Raynaud's phenomenon; Phase 2a study in Q4 2026
Covered in this story
Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.